Published Date: 26 Apr 2023
According to recent studies, the prevalence of HIV is 2.5 times higher in South London's mental health service users than it is in the general population. The article was released today in BMJ Open.
Read Full NewsAnemia Correction Before Colorectal Surgery Yields No Postoperative Gains
Mease discussed his hopes for the new approval's impact on the fibromyalgia field.
The rheumatology month in review emphasizes new approvals and the latest comparative research.
Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.
Q3 2025 saw a number of exciting approvals and data on promising therapies in development.
Prajapati discussed the impact of the expanded approval of guselkumab to pediatric PsO and psoriatic arthritis.
Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.
1.
BTK Inhibitor Active in Half of Patients With Richter Transformation
2.
Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.
3.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
The pathology of incurable cancers can be predicted thanks to research.
1.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
2.
Unlocking the Mystery of Granulomas: A Closer Look at the Causes and Treatment
3.
Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence
4.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
5.
Navigating the Unknown: How to Cope with Anaplastic Thyroid Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
2.
Navigating the Complexities of Ph Negative ALL - Part VIII
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation